Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

204.00 

4.00 2.0%

as of Sep 24 '19

52 Week Range:

109.00 204.50


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Virbac SA produces and sells medicines and vaccines for companion and food-producing animals. The company offers Canigen vaccines; Clostrisan, a vaccine for the prevention of clostridiosis and botulism; Deltanil, a deltamethrin-based parasiticide for topical application; Effitix to treat tick, flea, and mosquito infestations; Epiotic, an ear cleanser; Eradia for the treatment of clostridium infections and giardiasis; and Fort Up, an injectable solution to control and treat gastro-intestinal and pulmonary parasiticides. It also provides Iverhart and Iverhart Max Soft Chew, a chewable tablets to prevent heartworm disease, as well as treat and control roundworms, hookworms, and tapeworms; Maxflor Duo/Maxflin, an antibiotic for the prevention and treatment of respiratory diseases; Milteforan, an oral treatment for canine leishmaniosis; Moxiheart, an internal parasiticide; and Multimin, a trace element injectable supplement. In addition, the company offers Nutribond to enhance dietary; Prinovox, an ectoparasiticide; Propofol, an anesthetic; Rilexine, a cephalexin-based antibiotic; Sentinel Flavor Tabs and Sentinel Spectrum, a polyvalent parasiticide tablets; Shotapen, a combination of antibiotics to treat bacterial infections; Speed Reader, a blood marker dosage analyzer; and Suprelorin, an implant to induce temporary infertility in male dogs. Further, it provides Tridectin, a parasiticide oral solution; Veterin, an antibiotic; Veterinary HPM, a petfood; and Zoletil, a multi-species general anaesthetic. Additionally, the company is involved in the production of moldings for third parties. It operates in France, rest of Europe, North America, Latin America, Asia, Pacific, and Africa and the Middle East. Virbac SA was founded in 1968 and is headquartered in Carros, France.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 22.77
26.81
34.59
36.46
41.11
41.63
44.91
51.09
52.56
56.04
53.45
growth rate 17.7% 29.0% 5.4% 12.8% 1.3% 7.9% 13.8% 2.9% 6.6% -4.6%
Earnings BIT 50.39
56.36
86.13
83.50
95.46
105.44
109.57
38.88
66.32
64.93
75.03
growth rate 11.9% 52.8% -3.1% 14.3% 10.5% 3.9% -64.5% 70.6% -2.1% 15.6%
Avg.PE 14.08
16.26
17.76
17.54
18.94
21.65
35.58
44.98
54.00
28.43
28.43
growth rate 15.5% 9.2% -1.2% 8.0% 14.3% 64.3% 26.4% 20.1% -47.4% 0.0%
ROA 8.97
9.16
13.10
10.25
9.41
7.02
5.72
0.68
2.43
-0.19
1.58
growth rate 2.1% 43.0% -21.8% -8.2% -25.4% -18.5% -88.1% 257.4% -100.0% 100.0%
ROE 18.60
17.97
23.77
18.81
20.26
17.12
16.06
2.16
7.60
-0.57
4.48
growth rate -3.4% 32.3% -20.9% 7.7% -15.5% -6.2% -86.6% 251.9% -100.0% 100.0%
ROIC 20.27
17.97
20.46
19.44
13.65
11.75
8.57
1.71
4.38
1.06
3.30
growth rate -11.4% 13.9% -5.0% -29.8% -13.9% -27.1% -80.1% 156.1% -75.8% 211.3%
Cur. Ratio 1.27
1.38
1.48
1.43
1.37
1.43
1.34
1.33
1.10
1.22
1.23
growth rate 8.7% 7.3% -3.4% -4.2% 4.4% -6.3% -0.8% -17.3% 10.9% 0.8%
Quick Ratio 0.74
0.30
0.90
0.81
0.69
0.71
0.98
0.67
0.49
0.54
0.53
growth rate -59.5% 200.0% -10.0% -14.8% 2.9% 38.0% -31.6% -26.9% 10.2% -1.9%
Leverage 2.08
1.86
1.78
1.89
2.39
2.48
3.08
3.26
2.99
2.93
2.77
growth rate -10.6% -4.3% 6.2% 26.5% 3.8% 24.2% 5.8% -8.3% -2.0% -5.5%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 0.00
75.00
107.00
116.00
145.00
170.74
204.28
239.69
178.37
158.14
140.87
growth rate 42.7% 8.4% 25.0% 17.8% 19.6% 17.3% -25.6% -11.3% -10.9%
Acct.Payable 72.00
62.00
74.00
77.65
82.98
114.78
99.13
105.67
86.80
growth rate -13.9% 19.4% 4.9% 6.9% 38.3% -13.6% 6.6% -17.9%
Cur.Assets 168.80
186.30
253.00
259.00
324.00
351.09
750.80
485.50
433.51
400.60
407.55
growth rate 10.4% 35.8% 2.4% 25.1% 8.4% 113.9% -35.3% -10.7% -7.6% 1.7%
Total Assets 412.70
434.50
534.00
589.00
828.00
896.23
1,325.84
1,430.55
1,417.16
1,277.31
1,272.81
growth rate 5.3% 22.9% 10.3% 40.6% 8.2% 47.9% 7.9% -0.9% -9.9% -0.4%
Cash 8.40
14.10
40.00
24.00
40.00
34.97
375.91
51.16
48.45
48.38
62.81
growth rate 67.9% 183.7% -40.0% 66.7% -12.6% 974.9% -86.4% -5.3% -0.2% 29.8%
Inventory 69.90
70.60
99.00
112.00
132.00
138.78
159.87
182.31
197.91
184.76
195.78
growth rate 1.0% 40.2% 13.1% 17.9% 5.1% 15.2% 14.0% 8.6% -6.6% 6.0%
Cur.Liabilities 132.20
135.30
170.00
181.00
236.00
244.89
557.70
364.08
393.10
328.50
331.27
growth rate 2.3% 25.7% 6.5% 30.4% 3.8% 127.7% -34.7% 8.0% -16.4% 0.8%
Liabilities 211.60
200.90
231.00
275.00
429.00
481.86
843.65
948.26
896.37
798.49
776.93
growth rate -5.1% 15.0% 19.1% 56.0% 12.3% 75.1% 12.4% -5.5% -10.9% -2.7%
LT Debt 0.00
34.50
32.00
71.00
146.00
179.80
221.69
518.56
433.14
408.26
374.28
growth rate -7.3% 121.9% 105.6% 23.2% 23.3% 133.9% -16.5% -5.7% -8.3%
Equity 201.00
236.20
302.40
313.90
398.40
360.93
431.34
438.41
473.63
436.33
460.31
growth rate 17.5% 28.0% 3.8% 26.9% -9.4% 19.5% 1.6% 8.0% -7.9% 5.5%
Common Shares 9.00
9.00
9.00
8.00
8.00
8.00
8.00
8.00
8.00
8.00
8.00
growth rate 0.0% 0.0% -11.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 13.80
19.80
22.00
38.00
29.00
54.80
35.69
37.02
34.38
31.54
25.82
growth rate 43.5% 11.1% 72.7% -23.7% 89.0% -34.9% 3.7% -7.1% -8.3% -18.1%
Cash Dividends 9.50
10.40
11.40
13.00
14.70
16.02
16.01
16.01
growth rate 9.5% 9.6% 14.0% 13.1% 9.0% 0.0% 0.0%
Cash From OA 42.30
64.80
84.00
62.00
97.00
73.63
76.45
46.22
142.45
107.81
83.62
growth rate 53.2% 29.6% -26.2% 56.5% -24.1% 3.8% -39.5% 208.2% -24.3% -22.4%
FCF per Share 2.75
4.91
6.80
2.02
7.26
1.32
3.26
3.91
6.38
9.36
7.81
growth rate 78.6% 38.5% -70.3% 259.4% -81.8% 147.0% 19.9% 63.2% 46.7% -16.6%
Sale Purchase of Stock 0.51
0.51
0.05
growth rate 0.0% -90.4%
FCF 24.00
43.00
59.00
18.00
61.00
14.00
36.00
4.00
102.00
70.00
50.00
growth rate 79.2% 37.2% -69.5% 238.9% -77.1% 157.1% -88.9% 2,450.0% -31.4% -28.6%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 443.40
467.40
573.00
623.00
695.00
736.08
773.12
852.62
871.83
861.88
868.93
growth rate 5.4% 22.6% 8.7% 11.6% 5.9% 5.0% 10.3% 2.3% -1.1% 0.8%
Op.Income 54.40
58.30
64.00
59.00
67.00
105.44
109.57
38.88
66.32
64.93
75.03
growth rate 7.2% 9.8% -7.8% 13.6% 57.4% 3.9% -64.5% 70.6% -2.1% 15.6%
IBT 50.40
56.40
86.10
83.50
95.50
94.73
99.68
14.61
52.85
41.00
41.35
growth rate 11.9% 52.7% -3.0% 14.4% -0.8% 5.2% -85.4% 261.9% -22.4% 0.9%
Net Income 36.30
39.70
64.00
59.00
67.00
60.52
63.60
9.41
34.65
-2.58
20.10
growth rate 9.4% 61.2% -7.8% 13.6% -9.7% 5.1% -85.2% 268.4% -100.0% 100.0%
EPS 4.11
4.48
7.32
6.83
7.91
7.18
7.54
1.12
4.11
-0.31
2.39
growth rate 9.0% 63.4% -6.7% 15.8% -9.2% 5.0% -85.2% 267.0% -100.0% 100.0%
Gross Profit 298.30
315.90
391.00
428.00
480.00
504.66
528.51
554.77
571.68
558.44
574.64
growth rate 5.9% 23.8% 9.5% 12.2% 5.1% 4.7% 5.0% 3.1% -2.3% 2.9%

Quarterly Statements

Item Name Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Earnings BIT 18.76
18.76
18.76
28.70
28.70
growth rate 0.0% 0.0% 53.0% 0.0%
Balance Sheet Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 161.46
140.87
140.87
156.86
156.86
growth rate -12.8% 0.0% 11.4% 0.0%
Acct.Payable 98.58
86.80
86.80
82.34
82.34
growth rate -11.9% 0.0% -5.1% 0.0%
Cur.Assets 425.96
407.55
407.55
447.18
447.18
growth rate -4.3% 0.0% 9.7% 0.0%
Total Assets 1,304.47
1,272.81
1,272.81
1,325.02
1,325.02
growth rate -2.4% 0.0% 4.1% 0.0%
Cash 55.45
62.81
62.81
70.87
70.87
growth rate 13.3% 0.0% 12.8% 0.0%
Inventory 197.20
195.78
195.78
208.86
208.86
growth rate -0.7% 0.0% 6.7% 0.0%
Cur.Liabilities 317.92
331.27
331.27
307.14
307.14
growth rate 4.2% 0.0% -7.3% 0.0%
Liabilities 817.83
776.93
776.93
799.80
799.80
growth rate -5.0% 0.0% 2.9% 0.0%
LT Debt 435.48
374.28
374.28
398.74
398.74
growth rate -14.1% 0.0% 6.5% 0.0%
Equity 450.17
460.31
460.31
488.90
488.90
growth rate 2.3% 0.0% 6.2% 0.0%
Common Shares 10.57
10.57
10.57
10.57
10.57
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 6.58
6.34
6.34
3.83
3.83
growth rate -3.7% 0.0% -39.6% 0.0%
Cash Dividends
growth rate
Cash From OA 0.77
41.05
41.05
11.77
11.77
growth rate 5,258.4% 0.0% -71.3% 0.0%
Sale Purchase of Stock
growth rate
FCF -5.81
34.71
34.71
7.95
7.95
growth rate 100.0% 0.0% -77.1% 0.0%
Income Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Sales 214.98
219.49
219.49
231.87
231.87
growth rate 2.1% 0.0% 5.6% 0.0%
Op.Income 18.76
18.76
18.76
28.70
28.70
growth rate 0.0% 0.0% 53.0% 0.0%
IBT 12.33
8.34
8.34
20.68
20.68
growth rate -32.4% 0.0% 147.9% 0.0%
Net Income 6.13
3.92
3.92
13.22
13.22
growth rate -36.2% 0.0% 237.6% 0.0%
Gross Profit 142.49
144.83
144.83
155.62
155.62
growth rate 1.7% 0.0% 7.5% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (16.61)

YOY Growth Grade:

E (27.09)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 50.15 50.15 22.73
EPS / Growth -19.6% 4.07 13.8%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 4.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 2.6% 2.6%
Future PE 2.00 26.03 26.03
Future EPS 4.49 5.26 5.26
Value Price
MOS %
2.22
-98.9%
33.83
-83.4%
33.83
-83.4%
MOS Price 1.11 16.92 16.92
IRT 40.51 31.95 31.95

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.